

Quarterly Cash Flow Report of EBR Systems, Inc.

Sunnyvale, California; 19 March 2026: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing device for heart failure, is pleased to release a Quarterly Cash Flow Report for the quarter ended 31 December 2025. This report supplements the Company’s Form 10-K (audited annual financial report) filed with the U.S. Securities and Exchange Commission and released to the ASX earlier today.

Key Highlights:

- Payments for research and development trended up as the Company began enrolment in the post-approval study, and an increased development spending.
- Advertising and marketing costs increased to support commercialization.
- Administration and corporate costs trended higher, primarily due to the prepayment of the Company’s annual D&O insurance premiums.

	(Unaudited)				
	Quarter ended				Year ended
(In thousands, denominated in US\$)	31 Mar 2025	30 Jun 2025	30 Sept 2025	31 Dec 2025	31 Dec 2025
Cash flows from operating activities					
Receipts from customers	\$ -	\$ 12	\$ 470	\$ 1,190	\$ 1,672
Payments for					
research and development	(1,628)	(371)	(1,490)	(3,008)	(6,497)
product manufacturing and operating costs	(2,253)	(1,380)	(1,975)	(2,076)	(7,684)
advertising and marketing	(377)	(519)	(1,416)	(1,402)	(3,714)
leased assets	(159)	(161)	(258)	(162)	(740)
staff costs	(6,530)	(6,742)	(6,775)	(7,718)	(27,765)
administration and corporate costs	(1,788)	(1,525)	(1,272)	(2,536)	(7,121)
Interest received	420	499	552	409	1,880
Interest and other costs of finance paid	(1,249)	(1,289)	(1,269)	(1,228)	(5,035)
Income taxes paid	-	(1)	-	-	(1)
Government grants and tax incentives	-	-	293	3	296
Other - reimbursement of leasehold improvements	-	-	-	1,517	1,517
Net cash from / (used in) operating activities	(13,564)	(11,477)	(13,140)	(15,011)	(53,192)
Cash flows from investing activities					
Payments to acquire or for:					
property, plant and equipment	(60)	(889)	(1,277)	(1,457)	(3,683)
investments	-	(9,370)	(38,804)	(6,526)	(54,700)
Proceeds from disposal of:					
investments	17,967	11,154	20,998	16,100	66,219
Net cash from / (used in) investing activities	17,907	895	(19,083)	8,117	7,836
Cash flows from financing activities					
Proceeds from issues of equity securities	-	48,828	-	-	48,828
Proceeds from exercise of options	264	168	147	68	647
Transaction costs related to issue of equity securities	-	(2,313)	(285)	(11)	(2,609)
Repayment of borrowings	(22)	(15)	-	-	(37)
Net cash from / (used in) financing activities	242	46,668	(138)	57	46,829
Cash and cash equivalents at beginning of period	6,918	11,504	47,597	15,245	6,918
Net cash from / (used in) operating activities	(13,564)	(11,477)	(13,140)	(15,011)	(53,192)
Net cash from / (used in) investing activities	17,907	895	(19,083)	8,117	7,836
Net cash from / (used in) financing activities	242	46,668	(138)	57	46,829
Effect of movement in exchange rates on cash held	1	7	9	(10)	7
Cash and cash equivalents at end of period	\$ 11,504	\$ 47,597	\$ 15,245	\$ 8,398	\$ 8,398

ENDS

This announcement has been authorised for release by the Routine Disclosure Committee, a Committee of the Board.

For more information, please contact:

Company

Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: info@ebrsystemsinc.com

Investor Relations

Gabriella Hold
The Capital Network
P: +61 2 8999 3699
E: gaby@thecapitalnetwork.com.au

Julia Maguire
The Capital Network
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

About EBR Systems

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems' current expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC's website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.